Australia markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.67+0.40 (+6.38%)
At close: 04:00PM EDT
6.67 0.00 (0.00%)
After hours: 04:09PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 412.69M
Enterprise value 454.35M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.76
Price/book (mrq)74.89
Enterprise value/revenue 5.09
Enterprise value/EBITDA -2.50

Trading information

Stock price history

Beta (5Y monthly) 0.42
52-week change 3-68.79%
S&P500 52-week change 3-11.60%
52-week high 321.68
52-week low 33.28
50-day moving average 35.69
200-day moving average 36.41

Share statistics

Avg vol (3-month) 31.22M
Avg vol (10-day) 31.03M
Shares outstanding 563.01M
Implied shares outstanding 6N/A
Float 856.34M
% held by insiders 10.98%
% held by institutions 184.46%
Shares short (30 May 2022) 411.56M
Short ratio (30 May 2022) 47.71
Short % of float (30 May 2022) 426.03%
Short % of shares outstanding (30 May 2022) 418.35%
Shares short (prior month 28 Apr 2022) 48.78M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -263.04%
Operating margin (ttm)-209.28%

Management effectiveness

Return on assets (ttm)-37.59%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)89.31M
Revenue per share (ttm)2.37
Quarterly revenue growth (yoy)136.10%
Gross profit (ttm)-41.74M
EBITDA -186.28M
Net income avi to common (ttm)-234.9M
Diluted EPS (ttm)-6.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)218.5M
Total cash per share (mrq)3.47
Total debt (mrq)527M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.68
Book value per share (mrq)-4.08

Cash flow statement

Operating cash flow (ttm)-213.73M
Levered free cash flow (ttm)-168.88M